DOP2011000135A - Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1 - Google Patents
Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1Info
- Publication number
- DOP2011000135A DOP2011000135A DO2011000135A DO2011000135A DOP2011000135A DO P2011000135 A DOP2011000135 A DO P2011000135A DO 2011000135 A DO2011000135 A DO 2011000135A DO 2011000135 A DO2011000135 A DO 2011000135A DO P2011000135 A DOP2011000135 A DO P2011000135A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- modulators
- positive
- benzoquinazolinona
- allosterics
- aril
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/19—Acids containing three or more carbon atoms
- C07C53/21—Acids containing three or more carbon atoms containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La presente invención se refiere a compuestos de benzoquinazilinona de fórmula (I) Ios cuales son moduladores alostéricos positivos del receptor M1 y que son útiles en el tratamiento de enfermedades en las que el receptor M 1 está implicado, tales como enfermedad de Alzheimer, esquizofrenia y trastornos por dolor o del sueño. La invención también se refiere a composiciones farmacéuticas que comprenden Ios compuestos y aI uso de Ios compuestos y composiciones en eI tratamiento de enfermedades mediadas por el receptor M1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19974008P | 2008-11-20 | 2008-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2011000135A true DOP2011000135A (es) | 2011-07-31 |
Family
ID=41565956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2011000135A DOP2011000135A (es) | 2008-11-20 | 2011-05-12 | Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1 |
Country Status (37)
Country | Link |
---|---|
US (4) | US8557832B2 (es) |
EP (1) | EP2358686B1 (es) |
JP (1) | JP5102397B2 (es) |
KR (1) | KR101305590B1 (es) |
CN (1) | CN102292323B (es) |
BR (1) | BRPI0921924A2 (es) |
CA (1) | CA2743562C (es) |
CO (1) | CO6361928A2 (es) |
CR (1) | CR20110268A (es) |
CY (1) | CY1113665T1 (es) |
DK (1) | DK2358686T3 (es) |
DO (1) | DOP2011000135A (es) |
EA (1) | EA019098B1 (es) |
EC (1) | ECSP11011066A (es) |
ES (1) | ES2393694T3 (es) |
GE (1) | GEP20156348B (es) |
GT (1) | GT201100127A (es) |
HK (1) | HK1154587A1 (es) |
HN (1) | HN2011001358A (es) |
HR (1) | HRP20120992T1 (es) |
IL (1) | IL212573A (es) |
MA (1) | MA32898B1 (es) |
MX (1) | MX2011005284A (es) |
MY (1) | MY162502A (es) |
NI (1) | NI201100100A (es) |
NZ (1) | NZ592961A (es) |
PE (1) | PE20120031A1 (es) |
PL (1) | PL2358686T3 (es) |
PT (1) | PT2358686E (es) |
RS (1) | RS52528B (es) |
SG (1) | SG171769A1 (es) |
SI (1) | SI2358686T1 (es) |
SV (1) | SV2011003912A (es) |
TN (1) | TN2011000209A1 (es) |
UA (1) | UA100459C2 (es) |
WO (1) | WO2010059773A1 (es) |
ZA (1) | ZA201103612B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2915812A1 (en) * | 2009-08-31 | 2015-09-09 | Merck Sharp & Dohme Corp. | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators |
US8895580B2 (en) | 2009-10-21 | 2014-11-25 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone M1 receptor positive allosteric modulators |
WO2011075371A1 (en) * | 2009-12-14 | 2011-06-23 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone m1 receptor positive allosteric modulators |
KR101494059B1 (ko) | 2009-12-17 | 2015-02-16 | 머크 샤프 앤드 돔 코포레이션 | 퀴놀린 아미드 m1 수용체 양성 알로스테릭 조절제 |
WO2011084371A1 (en) * | 2009-12-21 | 2011-07-14 | Merck Sharp & Dohme Corp. | Aminobenzoquinazolinone m1 receptor positive allosteric modulators |
US8557992B2 (en) | 2010-06-15 | 2013-10-15 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators |
US8697690B2 (en) | 2010-07-01 | 2014-04-15 | Merck Sharp & Dohme Corp. | Isoindolone M1 receptor positive allosteric modulators |
WO2012047702A1 (en) * | 2010-10-04 | 2012-04-12 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators |
WO2012158473A1 (en) | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators |
KR20140051403A (ko) | 2011-08-12 | 2014-04-30 | 바스프 에스이 | 안트라닐아미드 화합물 및 살충제로서의 그의 용도 |
AR088148A1 (es) | 2011-08-12 | 2014-05-14 | Basf Se | Compuestos de antranilamida y sus usos como plaguicidas |
WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
US9233911B2 (en) | 2012-01-10 | 2016-01-12 | Council Of Scientific & Industrial Research | Cu-mediated annulation for the production of 1-amino-2-naphthalenecarboxylic acid derivatives |
JP6211509B2 (ja) | 2012-03-02 | 2017-10-11 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
WO2014077401A1 (ja) | 2012-11-19 | 2014-05-22 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
US9975844B2 (en) | 2014-04-17 | 2018-05-22 | Sumitomo Chemical Company, Limited | Method for producing nitro compound |
US20180050018A1 (en) * | 2015-03-06 | 2018-02-22 | Chase Pharmaceuticals Corporation | Peripheral-anticholinergic muscarinic agonist combination |
US10323027B2 (en) * | 2015-06-26 | 2019-06-18 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor |
US20180250270A1 (en) | 2015-09-11 | 2018-09-06 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
US10308633B2 (en) | 2015-09-30 | 2019-06-04 | Merck Sharp & Dohme Corp. | Process for making M1 receptor positive allosteric modulators |
EP3356333A4 (en) * | 2015-09-30 | 2019-03-27 | Merck Sharp & Dohme Corp. | CRYSTAL FORMS OF AN M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR |
EP3366679B1 (en) * | 2015-10-20 | 2021-03-24 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
UA124764C2 (uk) | 2016-04-15 | 2021-11-17 | Еббві Інк. | Інгібітори бромодомену |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
CN109843056A (zh) * | 2016-10-14 | 2019-06-04 | 印度商皮埃企业有限公司 | 4-经取代之苯基胺衍生物及其通过对抗不要的植物病原性微生物而保护作物之用途 |
CN109906220A (zh) | 2016-11-01 | 2019-06-18 | 豪夫迈·罗氏有限公司 | 用于治疗cns相关疾病的1,3-二氢-1,4-苯并二氮杂*-2-硫酮化合物 |
WO2018212312A1 (ja) | 2017-05-19 | 2018-11-22 | 武田薬品工業株式会社 | スクリーニング方法 |
CA3113227A1 (en) | 2018-09-28 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
CN117043302A (zh) | 2021-03-18 | 2023-11-10 | 默克专利有限公司 | 用于有机电致发光器件的杂芳族化合物 |
WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP9802323A3 (en) | 1995-10-02 | 1999-08-30 | Hoffmann La Roche | Pyrimidine derivatives , process for producing them and pharmaceutical compositions containing them |
WO1998028281A1 (en) * | 1996-12-23 | 1998-07-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
ATE302199T1 (de) | 1998-10-16 | 2005-09-15 | Sumitomo Pharma | Quinalozinon-derivate |
JP2005089298A (ja) * | 2001-09-18 | 2005-04-07 | Japan Tobacco Inc | ナフタレン化合物及びその医薬用途 |
US20060233843A1 (en) * | 2003-02-19 | 2006-10-19 | Conn P J | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
BRPI0611537A2 (pt) * | 2005-05-04 | 2010-09-21 | Hoffmann La Roche | (3,4-diidro-quinazolin-2-il) -(2-arilóxi-etil)-aminas tendo uma atividade sobre o receptor de 5-ht |
WO2008002621A2 (en) * | 2006-06-28 | 2008-01-03 | Merck & Co., Inc. | Benzyl-substituted quinolone m1 receptor positive allosteric modulators |
WO2012047702A1 (en) * | 2010-10-04 | 2012-04-12 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators |
-
2009
- 2009-11-19 NZ NZ592961A patent/NZ592961A/xx not_active IP Right Cessation
- 2009-11-19 PL PL09761104T patent/PL2358686T3/pl unknown
- 2009-11-19 JP JP2011537601A patent/JP5102397B2/ja active Active
- 2009-11-19 WO PCT/US2009/065060 patent/WO2010059773A1/en active Application Filing
- 2009-11-19 KR KR1020117011415A patent/KR101305590B1/ko active IP Right Grant
- 2009-11-19 CA CA2743562A patent/CA2743562C/en active Active
- 2009-11-19 GE GEAP200912265A patent/GEP20156348B/en unknown
- 2009-11-19 SI SI200930460T patent/SI2358686T1/sl unknown
- 2009-11-19 BR BRPI0921924A patent/BRPI0921924A2/pt active Search and Examination
- 2009-11-19 MX MX2011005284A patent/MX2011005284A/es active IP Right Grant
- 2009-11-19 EA EA201170705A patent/EA019098B1/ru not_active IP Right Cessation
- 2009-11-19 SG SG2011036472A patent/SG171769A1/en unknown
- 2009-11-19 EP EP09761104A patent/EP2358686B1/en active Active
- 2009-11-19 CN CN200980155011.4A patent/CN102292323B/zh active Active
- 2009-11-19 ES ES09761104T patent/ES2393694T3/es active Active
- 2009-11-19 DK DK09761104.0T patent/DK2358686T3/da active
- 2009-11-19 PE PE2011001058A patent/PE20120031A1/es not_active Application Discontinuation
- 2009-11-19 RS RS20120522A patent/RS52528B/en unknown
- 2009-11-19 PT PT97611040T patent/PT2358686E/pt unknown
- 2009-11-19 MY MYPI2011002215A patent/MY162502A/en unknown
- 2009-11-19 US US13/129,593 patent/US8557832B2/en active Active
- 2009-11-19 UA UAA201107595A patent/UA100459C2/ru unknown
-
2011
- 2011-04-28 IL IL212573A patent/IL212573A/en not_active IP Right Cessation
- 2011-04-29 TN TN2011000209A patent/TN2011000209A1/fr unknown
- 2011-05-12 DO DO2011000135A patent/DOP2011000135A/es unknown
- 2011-05-17 NI NI201100100A patent/NI201100100A/es unknown
- 2011-05-17 ZA ZA2011/03612A patent/ZA201103612B/en unknown
- 2011-05-17 GT GT201100127A patent/GT201100127A/es unknown
- 2011-05-19 HN HN2011001358A patent/HN2011001358A/es unknown
- 2011-05-20 SV SV2011003912A patent/SV2011003912A/es unknown
- 2011-05-20 EC EC2011011066A patent/ECSP11011066A/es unknown
- 2011-05-20 CR CR20110268A patent/CR20110268A/es unknown
- 2011-05-24 CO CO11063884A patent/CO6361928A2/es active IP Right Grant
- 2011-06-13 MA MA33939A patent/MA32898B1/fr unknown
- 2011-08-25 HK HK11108976.8A patent/HK1154587A1/xx not_active IP Right Cessation
-
2012
- 2012-12-03 HR HRP20120992AT patent/HRP20120992T1/hr unknown
- 2012-12-17 CY CY20121101227T patent/CY1113665T1/el unknown
-
2013
- 2013-08-29 US US14/013,184 patent/US8883810B2/en active Active
-
2014
- 2014-10-08 US US14/509,580 patent/US20150031713A1/en not_active Abandoned
-
2015
- 2015-08-17 US US14/828,216 patent/US9708273B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2011000135A (es) | Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1 | |
NI201200107A (es) | Moduladores alostéricos positivos de receptores m1 de la quinolina amida | |
CO6501188A2 (es) | Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1 | |
EP2582676A4 (en) | POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS | |
ATE530544T1 (de) | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren | |
CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
ATE475650T1 (de) | Positive allosterische chinolon-m1- rezeptormodulatoren | |
BR112014023384A2 (pt) | inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos | |
GB2511685A (en) | Muscarinic m1 receptor agonists | |
ECSP11010947A (es) | Compuestos n- sulfonamido pirazolil policíclicos | |
CL2008001820A1 (es) | Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer. | |
CL2009000491A1 (es) | Compuestos derivados de 3-(4-(2-oxoindol)-piperidin)-pirrolidinas y 3-(4-benzo[b]imidazol)-piperidin)-pirrolidinas sustituidas proceso de preparacion; composicion farmaceutica; compuestos intermediarios; utiles en el tratamiento de la terapia del dolor, de enfermedades tales como alzheimer, ansiedad, depresion y glaucoma. | |
ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
CL2009000445A1 (es) | Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion. | |
CL2012002259A1 (es) | Forma cristalina de 4-{(1s,2s)-2-[84-ciclobutilpiperazin-1-il-carbonil]ciclopropil}benzamida; composicion farmacéutica; y su uso para tratar enfermedades tales como esquizofrenia, narcolepsia, somnolencia diurna excesiva, obesidad, trastornos por deficit de atencion con hiperactividad, dolor, entre otras. | |
TW200833697A (en) | Spiro-piperidine derivatives | |
WO2009134668A3 (en) | 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators | |
WO2009117283A3 (en) | Quinolizidinone m1 receptor positive allosteric modulators | |
MX2009005504A (es) | Derivados de espiro piperidina como antagonistas del receptor via. | |
CO6541615A2 (es) | Tiazoles bicíclicos como moduladores alostéricos de receptores mglur5 | |
MX2009006920A (es) | Indoles. | |
JO2919B1 (en) | Aryl methyl benzocoinazolinone M1 positive allosteric modulation receptor | |
EA201270825A1 (ru) | Применение производного эстрогена для производства фармацевтических композиций, пригодных для лечения и/или предотвращения психиатрических заболеваний, и для лечения и предотвращения указанных заболеваний |